Cigarettes with ultralow nicotine levels are now being called the game-changer in the fight against smoking. If you are having trouble in quitting smoking, then, it is for you, that soon the Biden White House is expected to formally propose a plan that will order cigarette nicotine levels to be reduced, reports The Washington Post. For now though, it has been a failure, as these cigarettes, also known as VLN cigarettes that stands for very low nicotine are only available in 5,100 stores in 26 states. This is a very small fraction of the overall market for cigarettes. The company that makes it, 22nd Century, is struggling not because of the low supply, but also from the advocates who have long believed slashing nicotine levels altogether.

The Advent and ideation

Nicotine is a chemical that is produced naturally from tobacco that makes the cigarette and also keeps people hooked. While it is believed that it makes people alert, and get the "hit" to keep them going, it exposes the users to harmful substances, carcinogens, and increases the risk of heart disease, lung cancer, and other illness.

Ultralow-nicotine cigarettes, like the VLN brand, contain about 95% less nicotine than the regular cigarettes. The idea is quite simple: without the addictive grip of nicotine, smokers will find it easier to quit. Research too has shown some promise. For instance, the studies funded by the National Institute on Drug Abuse revealed that very low nicotine cigarettes reduced addiction potential significantly without having users to increase their smoking frequency. However, the problem is, why would anyone choose for a low-nicotine that does not make them feel the same way, when the high-nicotine cigarette is right next to it, making them feel the same way, with the same alertness, sold at the same price.

“It’s very hard to imagine someone actively choosing to continue to use a low-nicotine product for the same price when a high-nicotine product is right next to it,” said Eric Donny, a Wake Forest University School of Medicine nicotine researcher.

No wonder, the experiment with low nicotine product by Philip Morris' Next cigarettes in the 1980s and Vector Tobacco's Quest brand in the early 2000s, flopped.

FDA's Role in the Push

The Food and Drug Administration (FDA) has supported the development of such products, even allowing VLN cigarettes to be marketed as lower-risk options. However, these products remain a niche market, available in only a fraction of U.S. stores.

Recently, the Biden administration has considered a bold step—mandating a dramatic reduction in nicotine levels for all cigarettes sold in the United States. Supporters believe this move could save millions of lives, while critics, including tobacco companies, warn of potential unintended consequences.

What Could Be The Challenges?

Resistance from Big Tobacco Companies: They could argue that slashing nicotine levels could backfire. Their claim is, smokers will turn to black markets or smoke more to satisfy their cravings, which may lead to greater exposure to harmful substances.

Consumer Reluctance: History is proof to the instances of smokers being hesitant to embrace the low-nicotine products.

Political Hurdle: It may face political roadblocks, as under the Trump administration, plans to cut nicotine were shelved.

Could Low-Nicotine Cigarettes Be The Solution?

Advocates believe that ultralow-nicotine cigarettes could be a game-changer, comparing them to decaf coffee or non-alcoholic beer—products that reduce harm while offering a similar experience.

Some experts warn that a black market for traditional cigarettes could undermine these efforts. They also stress the need for safer alternatives, such as vaping products, to support smokers transitioning away from traditional cigarettes.

Female high school students in the United States had lower overall cardiovascular health scores than male students, with mean scores of 64.2 and 66.2, respectively, according to a nationwide survey by the US Centers for Disease Control and Prevention (CDC).

The findings, based on the American Heart Association’s Life’s Essential 8 framework, showed that female students had lower mean scores for physical activity and sleep health but higher, more favorable BMI scores than male students.

Lower physical activity and sleep health scores were also observed among students in higher grades, while nicotine exposure scores were lower among students in higher grades.

CDC Study Assesses Heart Health Among US Teenagers

Also read: 4 in 10 US High School Students Report Binge Eating: What Are the Risks?

The 2025 biennial Youth Risk Behavior Survey included 10,710 students in grades 9–12. Of these, 5,192 had complete data for all five cardiovascular health measures: physical activity, diet, sleep health, body mass index (BMI), and nicotine exposure.

The findings, published in the CDC’s Morbidity and Mortality Weekly Report, showed that approximately 21% of students had high overall cardiovascular health scores, while 61% had moderate scores and 18% had low scores.

The prevalence of high overall scores was lower among female students and those in grades 10–12 than among male students and ninth-graders, respectively. Overall, approximately four in five students had low or moderate scores across the five assessed cardiovascular health measures.

Why Sleep, Diet and Exercise Matter for Teen Heart Health

Read More: The Silent Struggle Of Raising A Child With Mental Health Challenges: How Parents Can Cope With Stigma

Cardiovascular diseases (CVDs) are the leading causes of mortality in the US, and many CVD risk factors emerge in childhood and adolescence. Adolescence is a crucial period during which health behaviors develop and persist into adulthood.

A March 2026 study published in the European Journal of Preventive Cardiology suggested that even small, combined improvements in daily habits may benefit cardiovascular health.

Sleeping an additional 11 minutes, engaging in five more minutes of moderate-to-vigorous physical activity, and eating an extra quarter-cup of vegetables daily were associated with a 10% lower risk of heart attacks, strokes and other serious cardiovascular problems compared with less healthy habits.

Sleep is particularly important during adolescence, when the body and brain undergo significant developmental changes. Adequate sleep supports physical recovery, immune function, concentration and emotional well-being.

Teenagers generally need eight to 10 hours of sleep each night. However, schoolwork, extracurricular activities and screen time can interfere with sufficient rest. Research has also linked insufficient sleep with less healthy food choices and a greater tendency to eat later at night.

Elsie Taveras, a pediatrician at Mass General Brigham, highlights the importance of adequate sleep in reducing the risk of chronic conditions, including obesity and cardiovascular risk factors. Children from racial minority and lower-income households may face additional barriers to healthy sleep.

“Sleep health is something we need to pay attention to, and that we counsel teenagers and their families about,” Taveras said.

“We’ve found that shorter sleep duration and lower sleep quality in children and adolescents are associated with a higher risk of obesity and risk factors for heart disease. These are substantial effects that can affect children for years to come,” she added.

Dr Rachna Shroff, an Indian-American cancer researcher at the University of Arizona, has died at the age of 47 from an aggressive form of cancer she had spent her career studying, the university announced.

Earlier this year, Shroff, associate director of clinical investigations at the University of Arizona Cancer Center, was diagnosed with incurable, terminal adenocarcinoma, a cancer that develops in glandular cells lining certain organs.

Dr Rachna Shroff’s Cancer Diagnosis

Dr Rachna first noticed a swollen lymph node in May. By the end of the month, the cancer had spread elsewhere in her body, and tests suggested it had likely originated in her stomach or intestine.

Her medical team initially suspected lymphoma, a type of blood cancer. Further testing later confirmed terminal adenocarcinoma.

“It’s been a journey,” Dr Rachna told NBC News in a Zoom interview shortly before her death. “I’ve spent my entire life trying to eradicate cancer, primarily pancreatic cancer, but also liver cancers.”

Also read: Swimmer Archie Goodburn’s Plea Prompts UK Brain Cancer Research Review

Dr Rachna Shroff’s Scientific Work

Dr Rachna was a clinician-scientist and internationally respected expert in cholangiocarcinoma, a rare cancer of the bile ducts. She authored more than 80 publications and participated in more than 130 professional engagements.

In September, despite her own life-limiting diagnosis, one of her final wishes was to establish the Conquer Cancer – Rachna Shroff, MD, MS, FASCO Endowed Young Investigator Award in Biliary Cancers. Within weeks, she achieved her goal of raising more than $1.35 million to support future cancer research and innovation.

A Career Dedicated to Advancing Cancer Treatment

READ: Survival In Aggressive Brain Tumors Improves By Up To 50% in India, Say Doctors

The daughter of a nephrologist mother and a biochemist father, Dr Rachna developed an early interest in cancer research in Tucson. As a high school student, she won the 1993 Osler Fellowship, which gave her the opportunity to work in the laboratory of Margaret Briehl, a University of Arizona Cancer Center member and professor at the College of Medicine – Tucson.

She completed her undergraduate studies at Brown University and earned her medical degree from Thomas Jefferson University. In 2010, she completed her fellowship at the University of Texas MD Anderson Cancer Center, where she subsequently served as an associate professor of gastrointestinal medical oncology from 2010 to 2018.

She returned to Tucson in 2018 after being recruited to the University of Arizona.

Dr Rachna became internationally recognized for her work in cholangiocarcinoma, focusing on a rare and historically difficult-to-treat disease at a time when treatment options were limited and no therapies had been approved by the US Food and Drug Administration specifically for the disease. The field has since advanced significantly, in part through landmark clinical trials she led as a principal investigator.

In a video recorded for a conference five years ago, Dr Rachna discussed how gastrointestinal cancer research was beginning to catch up with advances in better-known cancers.

“I will admit that we had a little bit of envy of the targeted therapy space in, say, lung cancer and breast cancer...but I think in the last decade or so, we have seen a dramatic improvement in terms of understanding the relevant targets for all of the different GI malignancies,” she told the 2021 Gastrointestinal Cancers Symposium.

Shroff was also renowned for her work developing novel therapies for pancreatic and hepatobiliary cancers.

Dr Rachna Shroff’s Family

Beyond her professional accomplishments, Dr Rachna's most cherished roles were those of wife, mother and friend.

She is survived by her husband, Dr Puneet Shroff, a professor of medicine and associate director of the Banner Medical Group’s Allergy Clinic; their children, Simran and Sachin.

The US Food and Drug Administration (FDA) is considering easing restrictions on certain peptides, potentially allowing specialty pharmacies to produce injections not approved for medical use, raising safety concerns.

The Department of Health and Human Services (HHS) has submitted an interim access policy for peptides to the White House for review, according to a government website posting on Thursday. The proposal was sent to the Office of Management and Budget, the Associated Press reported.

The list of peptides includes BPC-157, an unapproved peptide promoted online for pain relief, healing and performance enhancement, has gained popularity among wellness influencers and followers of Health Secretary Robert F. Kennedy Jr.'s Make America Healthy Again (MAHA) movement. A recent study found that its use increased 33-fold between 2020 and 2026.

What Is The FDA Planning?

Also read: RFK Jr-Backed ‘Wolverine’ Peptide Use Surges: Why Are People Taking An Unapproved Drug For Injury Recovery?

The proposal could allow compounding pharmacies to produce certain peptides, including BPC-157, according to AP, citing two people familiar with the matter

The policy would reportedly give pharmacies greater assurance that they would not face enforcement action for producing these substances.

Formally permitting peptides for compounding would require federal rulemaking, a process that could take years. It remains unclear whether the administration intends to pursue that route.

In July, an FDA advisory committee recommended allowing six of seven peptides under review to be used by compounding pharmacies for patients with prescriptions. The recommendation went against FDA staff concerns that there was insufficient evidence to establish their safety and effectiveness.

The proposal has drawn support from some peptide sellers. Telehealth companies Hims & Hers and Noom have also announced plans to offer peptides if federal restrictions are eased. Wall Street analysts estimate the market could be worth $2 billion to $3 billion.

What Are Peptides?

Peptides are short chains of amino acids that play various roles in the body, including regulating hormones and processes involved in growth, metabolism and healing. Some peptide-based medicines are approved for conditions such as diabetes and obesity.

However, other peptides promoted online have not been adequately studied or approved as medicines.

BPC-157 is often combined with TB-500, a peptide derived from thymosin beta-4, in a combination marketed as the “Wolverine stack.” It is promoted online for tissue repair and recovery from muscle, tendon and other injuries. BPC-157 is not approved by the FDA for medical use.

Read More: 4 in 10 US High School Students Report Binge Eating: What Are the Risks?

What Are The Safety Concerns?

The FDA has raised concerns about limited human safety data, potential immune reactions and impurities in BPC-157 products. It has also cited risks associated with certain compounded peptides, including contamination, allergic reactions and tumor growth.

The agency's adverse-event database includes reports of injection-site reactions, shortness of breath and skin or gum pigmentation changes among people who used BPC-157. However, these reports do not establish that the peptide caused the events.

Compounded medicines can meet specific patient needs, but they are not FDA-approved. The agency does not verify their safety, effectiveness and quality through the same premarket approval process used for approved drugs.

Allowing pharmacies to compound certain peptides would not mean the substances had received FDA approval or that their safety and effectiveness had been established.